Need professional-grade analysis? Visit stockanalysis.com
$218.28M
N/A
N/A
N/A
Inhibikase Therapeutics Inc (IKT) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.60, down 11.11% from the previous close.
Over the past year, IKT has traded between a low of $1.41 and a high of $2.39. The stock has lost 33.1% over this period. It is currently 33.1% below its 52-week high.
Inhibikase Therapeutics Inc has a market capitalization of $218.28M.
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.